Hidradenitis Suppurativa and Treatments

A data-driven precision medicine approach identifies sirolimus, pioglitazone, and fulvestrant as novel therapies for hidradenitis suppurativa by targeting disease gene signatures in immune cells.

This study identifies metabolic dysregulation of autophagy in HS, linking mTOR activation and cadaverine to inflammation, pain, and malodor.

This study uses single-cell RNA-sequencing and spatial transcriptomics to characterize keratinocyte states and fibroblast niches in severe HS lesions, revealing spatially distinct interactions that may explain treatment resistance.

This study uses single-cell RNA sequencing to identify distinct HF stem cell differentiation trajectories in HS patients, linking them to three clinical endotypes defined by inflammation, keratinization, and mixed features.

The paper identifies two molecular subtypes of hidradenitis suppurativa using transcriptomic data and validates their association with drug response.

This paper develops a whole-tissue explant model of hidradenitis suppurativa to study its pathogenesis and treatment efficacy in intact human tissue.

HS-OmicsDB aggregates bulk and single-cell RNA sequencing data from untreated HS patients to profile gene expression in specific tissue types and map cell-specific gene expression in HS lesions.

The paper identifies rare missense variants in the SH3 domain of PSTPIP1 as significantly enriched in hidradenitis suppurativa patients, suggesting shared genetic risk with PSTPIP1-related syndromes.